Key result
Amplatzer closure of ASD and PFO achieves ~94% procedural success with low complication rates.
Why the study?
Experience with transcatheter device closure of atrial septal defects in adults, especially with large defects, was limited.
Is transcatheter closure using the Amplatzer device safe and effective for treating atrial septal defects and patent foramen ovale in adult patients?
Observational (n=100)
No
Is transcatheter closure using the Amplatzer device safe and effective for treating atrial septal defects and patent foramen ovale in adult patients?
The Amplatzer device is an effective and safe method for transcatheter closure of interatrial defects in adults, with a learning curve of approximately 35 cases.
Early single-center experience supports procedural feasibility for large adult ASDs; leaves open need for randomized comparisons and long-term data.
BACKGROUND: Transcatheter device closure of atrial septal defects (ASD) is an alternative to surgery, but experience is limited in adults, especially in those with large (> 26 mm) defects. HYPOTHESIS: We investigated the safety, efficacy, and learning curve for closure of ASD and patent foramen ovale (PFO) using the Amplatzer device. METHODS: In all, 101 procedures were carried out in 100 consecutive adult patients in a single cardiac center between July 1998 and August 2002. RESULTS: Preprocedure diagnosis was ASD and PFO in 50 patients each. A device was deployed in 94 of 101 attempts (93%) in 94 of 100 patients (94%). Atrial septal defect device sizes were 10-38 mm, median 24 mm, and 40% were > 26 mm. Major complications occurred in 2 of 100 patients (2%). One ASD device displaced requiring surgery within 24 h and one patient with PFO experienced pericardial tamponade; there were no deaths. Local vascular complications occurred in 4 of 100 (4%) and late complications in 4 of 100 (4%) patients. Patent foramen ovale closure was quicker (p<0.001), required less radiation (p=0.04), and was associated with fewer local vascular complications than ASD closure (p=0.04). Deployment of ASD devices > 26 mm was not associated with increased complications, length of procedure, or radiation compared with devices < or = 26 mm (all p>0.05). Complications in the first 35 patients were more frequent than in subsequent patients: 7 of 35 (20%) versus 3 of 65 (4.6%) (p=0.04); procedure and fluoroscopy times (both p<0.001) and radiation doses (p=0.001) were also higher. CONCLUSION: The Amplatzer device is an effective method for transcatheter closure of interatrial defects in adults, including large ASDs up to 38 mm. Major complications are uncommon. A learning curve of approximately 35 cases was suggested by the decline of complications, procedure times, and radiation exposure.
No takes yet. Share an insight, caveat, or question.
Purcell et al. (2004) conducted an observational in Atrial septal defects (ASD) and patent foramen ovale (PFO) (n=100). Amplatzer device closure was evaluated on Device deployment success. Transcatheter closure of ASD and PFO using the Amplatzer device was successful in 94% of patients, with major complications occurring in 2%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: